Skip to main content

Tyenne

Pronunciation: tye-en
Generic name: tocilizumab-aazg
Dosage forms: injection for intravenous infusion, prefilled syringe for subcutaneous injection, prefilled autoinjector for subcutaneous injection
Drug class: Interleukin inhibitors

Medically reviewed by Carmen Pope, BPharm. Last updated on Mar 11, 2024.

What is Tyenne?

Tyenne (tocilizumab-aazg) is an injectable interleukin-6 (IL-6) receptor antagonist that may be used to treat:

Tyenne works by targeting and binding to a protein that is associated with inflammation called interleukin-6 (IL-6), inhibiting signaling through both soluble and membrane-bound IL-6 receptors. This proinflammatory cytokine is produced by a variety of immune system cells including T- and B-cells, lymphocytes, monocytes, and fibroblasts. It is also locally produced by synovial and endothelial cells in joints, contributing to inflammatory conditions such as rheumatoid arthritis.

Tyenne is a biosimilar to Actemra (tocilizumab) with both subcutaneous and IV formulations and was FDA-approved on March 5, 2024. A biosimilar is a biological product that is similar to a reference biologic and for which there are no clinically meaningful differences in terms of safety, purity, and potency.

Warnings

Serious and life-threatening hypersensitivity reactions have occurred with tocilizumab products, such as Tyenne, including anaphylaxis. Seek emergency help or tell your doctor immediately if you experience shortness of breath, throat tightness, swelling of the airways and throat, itching, low blood pressure, or hives.

Tyenne affects your immune system. You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, aches, tiredness, cough, skin sores, diarrhea, weight loss, or burning when you urinate.

Tyenne may also cause a perforation (a hole or tear) in your stomach or intestines. Tell your doctor if you have a fever and stomach pain with a change in your bowel habits.

Tyenne may also cause liver problems. Tell your doctor right away if you have right-sided stomach pain, vomiting, loss of appetite, tiredness, dark urine, clay-colored stools, or yellowing of your skin or eyes.

Before you start treatment with Tyenne, your doctor may perform tests to make sure you do not have tuberculosis or other infections. While using Tyenne, you may need frequent medical tests to monitor your blood counts, cholesterol, and liver function.

Ensure your vaccinations are up to date before starting treatment with Tyenne. Do not receive a "live" vaccine during treatment because you may develop a serious infection or the vaccine may not work as well and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster ( shingles), and nasal flu (influenza) vaccine.

It is not known if Tyenne is safe and effective in children with PJIA or SJIA under 2 years of age or in children with conditions other than PJIA or SJIA.

Before taking

Do not take Tyenne if you have had an allergic reaction to tocilizumab, or any of the inactive ingredients in the injection.

Before you receive Tyenne, tell your healthcare provider about all of your medical conditions, including if you:

Pregnancy

Tyenne may harm your unborn baby. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment.

Breastfeeding

It is not known if Tyenne passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment.

How is Tyenne administered?

Tyenne is given as an infusion into your vein (intravenously, IV) by a healthcare professional, or it can be given as a subcutaneous (SC) injection just under your skin.

Intravenous (IV) infusion

If your healthcare provider prescribes Tyenne as an IV infusion, you will receive Tyenne from a healthcare provider through a needle placed in a vein in your arm.

While taking Tyenne, you may continue to use other medicines that help treat your rheumatoid arthritis, PJIA, or SJIA such as methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs), and prescription steroids, as instructed by your healthcare provider.

Subcutaneous (SC) injection

You can learn how to administer subcutaneous (under the skin) injections yourself at home after adequate training, or they can be given by a healthcare provider. Do not try to inject Tyenne until you have been shown the right way to give the injections by your healthcare provider.

Tyenne is available as a single-dose prefilled syringe or single-dose prefilled autoinjector.

For more information go to www.tyenne.com or you can enroll in a patient support program by calling 1-833-522-4227 or visiting the patient support program website: www.kabicare.com.

What happens if I miss a dose?

Call your doctor for instructions if you miss a dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while receiving Tyenne?

Do not receive a "live" vaccine or you could develop a serious infection. The vaccine may not work as well and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), polio, rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster ( shingles), and nasal flu (influenza) vaccine.

You may still be able to receive a yearly flu shot, or an "inactivated" or other vaccine to prevent diseases such as hepatitis, meningitis, pneumonia, shingles, HPV, or whooping cough. Ask your doctor before getting any vaccine.

Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.

What are the side effects of Tyenne?

Tyenne can cause serious side effects including:

While rare, Multiple Sclerosis has been diagnosed in people who take Tyenne. It is not known what effect Tyenne may have on some nervous system disorders.

The most common side effects of Tyenne affecting at least 5% of people include:

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Fresenius Kabi USA, LLC at 1-800-551-7176.

What other drugs will affect Tyenne?

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Tell your healthcare provider about all of the medicines you take, including prescription, over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:

Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine. This list is not complete and many other drugs may interact with tocilizumab. See the Product Information for a complete list of interactions.

Storage

Keep Tyenne refrigerated at 36°F to 46°F (2ºC to 8ºC). Do not freeze.

A single prefilled syringe or autoinjector may be stored at room temperature at or below 77°F (25°C) for a single period of up to 14 days.

Protect from light by storing in the original package until the time of use. Keep syringes and autoinjectors dry.

Ingredients

Active ingredient: tocilizumab-aazg.

Inactive ingredients of intravenous and subcutaneous formulations: arginine, histidine, hydrochloric acid, lactic acid, polysorbate 80, sodium chloride, sodium hydroxide, and water for injection.

The IV infusion is available as 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), and 400 mg/20 mL (20 mg/mL) single-dose vials for further dilution before intravenous infusion.

The SC injection is available as a 162 mg/0.9 mL single-dose prefilled syringe or single-dose prefilled autoinjector.

Manufacturer

Fresenius Kabi USA LLC.

Popular FAQ

Actemra is used to treat several different conditions that have inflammation as a common characteristic, such as Rheumatoid arthritis (RA), Giant Cell Arteritis (GCA), Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), Polyarticular Juvenile Idiopathic arthritis (PJIA), Systemic Juvenile Idiopathic arthritis (SJIA), Cytokine Release Syndrome (CRS), and COVID-19.

Continue reading

More FAQ

References

  1. Product Label

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.